3 - France

Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

Read More

Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

June 30, 2026

Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its…

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

Read More

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

June 12, 2026

Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3…

Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Read More

Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

May 28, 2026

Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28,…